Pflug Koory’s Lineage Cell Therapeutics LCTX Stock Holding History

Pflug Koory’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-518	Closed	-$1K	–	424
2018 Q3	$1K	Hold	518	–	–	﹤0.01%	418
2018 Q2	$1K	Hold	518	–	–	﹤0.01%	423
2018 Q1	$1K	Hold	518	–	–	﹤0.01%	412
2017 Q4	$0	Hold	518	–	–	﹤0.01%	393
2017 Q3	$1K	Hold	518	–	–	﹤0.01%	395
2017 Q2	$1K	Hold	518	–	–	﹤0.01%	397
2017 Q1	$2K	Hold	518	–	–	﹤0.01%	382
2016 Q4	$2K	Buy	+518	New	+$1.59K	﹤0.01%	374

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Pflug Koory's LCTX Position: Q4 2018 in Review

Pflug Koory sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 518 shares — an estimated $1K sold.

Pflug Koory first reported a position in LCTX in Q4 2016 and held it in 8 quarters. The position peaked at $2K in Q1 2017. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

Pflug Koory reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
Pflug Koory sold 518 Lineage Cell Therapeutics shares in Q4 2018, an estimated $1K.
Pflug Koory first reported a position in Lineage Cell Therapeutics in Q4 2016 and held it in 8 quarters.
Pflug Koory's Lineage Cell Therapeutics position peaked at $2K in Q1 2017.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Pflug Koory's 13F filing for Q4 2018, filed 24 Jan 2019.